--

Ningxia Guiheyuan Biotechnology Development Co., Ltd. was established in June 2012 and is located in the Xinshui Agricultural Products Processing and Innovation Park in Zhongning County. It is a specialized, refined, characteristic, and innovative small and medium-sized enterprise as well as a technology-based small and medium-sized enterprise, with a registered capital of 9 million yuan. The company's business scope covers modern agricultural development, agricultural technology services, the acquisition and primary processing of agricultural products such as goji berries, food research, development, manufacturing, and sales, as well as import and export trade. The company owns 27 registered trademarks and 21 patent information, demonstrating strong innovation capabilities. In recent years, the company has been actively expanding its business areas and is committe

Bairuiyuan Goji Berry Co., Ltd. is a full industrial chain enterprise specializing in goji berry technology research and development, organic planting, production and processing, marketing, and cultural tourism. It has successively won honors such as "China's Well-known Trademark", "National Key Leading Enterprise in Agricultural Industrialization", "National High-tech Enterprise", and "National 4A-level Tourist Attraction". The Bairuiyuan model, which integrates the primary, secondary and tertiary industries, online and offline, and traditional and modern elements, is committed to fulfilling its mission of "enabling Chinese people to enjoy high-quality Chinese wolfberries", and is determined to become a respected century-old brand. In 2016, Bairuiyuan was awarded the "Autonomous Region Quality Award" by the Autonomous Region People's Government and was recognized as a "National Key Leading Enterprise in Agricultural Industrialization" by the Ministry of Agriculture and Rural Affairs of the People's Republic of China. In 2017, it was selected as a "Food Supply Enterprise" at the Xiamen Summit of BRICS Leaders. In 2018, it was selected as the National Professional Research and Devel

Established in April, 2002, Lanzhou Ion Therapy Co., Ltd. is a high-tech company, which is a subordinate to CAS Ion Medical Technology Co., Ltd. There are more than 400 employees, most of whom hold a bachelor's degree or higher; it is one of the few enterprises in China that has the qualifications and capabilities for the design, production, commissioning, operation and maintenance of heavy ion medical machine (ie carbon ion therapy systems); the company has successively passed ISO9001, 13485 quality management system certification, and obtained relevant qualifications such as Class III medical device production and operation license, Class I radiation device radiation safety license and other relevant qualifications.

AstraZeneca is a global, science-led biopharmaceutical company, based in Cambridge, UK. Since entering China in 1993, AstraZeneca has focused on the utmost needs of Chinese patients covering therapy areas of oncology, cardiovascular, renal, metabolism, respiratory, gastrointestinal, rare diseases, vaccine and antibody and immunology, bringing over 40 global innovative medicines to China. AstraZeneca has established its China headquarters in Shanghai, with two global strategic R&D centers located in Shanghai and Beijing. We have also established regional headquarters in Beijing, Guangzhou, Hangzhou, Chengdu and Qingdao. Our global manufacturing sites in Wuxi, Taizhou, and Qingdao are providing high quality medicines to over 70 global markets.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. Create a world where healthcare has no limits.

Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally.

Panasonic Group is a global leader in electronics manufacturing, offering advanced technologies and system solutions for residential, commercial, mobility, and consumer applications. Founded in 1918, the company has expanded worldwide with a steadfast commitment to "enhancing quality of life" and "promoting global cultural progress." Panasonic entered the Chinese mainland market in 1978 and now focuses on key areas such as "smart and healthy living environments," "components for new energy vehicles," and "smart manufacturing."

Winner Medical is a healthcare company headquartered in Shenzhen, Guangdong Province, China, that drives synergistic development between its medical and consumer divisions through two major brands: ""Winner Medical"" and ""Purcotton."" Winner Medical continuously innovates and expands its industry boundaries, with business operations now covering a wide range of sectors including healthcare, personal care, home care, maternal and infant care, and home textiles and apparel.

Dong E E Jiao Co., Ltd. (referred to as "Dong E E Jiao"), which belongs to the comprehensive health sector of China Resources Group. Dong E E Jiao, formerly known as Shandong Dong E E Jiao factory, was established in 1952, reorganized from a state-owned enterprise into a joint-stock enterprise in 1993, listed on the Shenzhen Stock Exchange in 1996, and formally joined China Resources Group in 2005. The company currently has over 4000 employees, a total asset of 13 billion yuan, brand value of 43.8 billion yuan and three well-known Chinese trademarks. The products are sold to more than 10 countries and regions, including Southeast Asia, Japan, South Korea and America, in addition to China.

Zhejiang Xingyue Biotechnogy Co., Ltd., founded in 2010 in Hangzhou Future Sci-Tech City, is a national high-tech enterprise established by a team of overseas-returned PhDs and China Xingyue Group. We integrate traditional silk materials with regenerative medicine to develop advanced healthcare solutions. Operates the world's first ISO13485-certified medical silk protein production line (6-ton annual capacity) 5,000㎡ GMP cleanrooms and labs Pioneer in industrializing medical silk materials Four industry-first medical applications: -China's first Class III silk fibroin wound dressing -First silk fibroin hernia repair mesh in clinical trials -First silk fibroin master file (M2021005-000) -Drafted China's silk protein industry standard R&D Ecosystem Hosts Zhejiang Provincial Key Lab for Tissue Engineering Collaborates with Zhejiang University, Zhejiang Sci-Tech University Executed national "863 Program" projects (2012, 2015) Vision To become a global leader in innovative medical materials by accelerating silk-based implantable device industrialization, fulfilling our mission: "Science for Health, Technology for Beauty" – bringing medical silk solutions worldwide.

Lanzhou Foci Pharmaceutical Co., Ltd., a "China Time-honored Brand" with nearly a century of pharmaceutical history, was established in Shanghai in 1929. It pioneered the concentrated pill form of traditional Chinese medicine and was the first Chinese enterprise to engage in the industrial manufacture of traditional Chinese medicine. Listed on the Shenzhen Stock Exchange in 2011, the company is dedicated to the production, contract manufacturing, and sales of traditional Chinese patent medicines and Chinese herbal materials. The Foci trademark is a China-famous trademark. As a high-tech enterprise, it currently boasts 8 R&D platforms, 467 production approval numbers, and 10 exclusive products. Foci products have always maintained a 100% market inspection pass rate. They have been exported to 32 countries and regions across the globe. For many years, the company has consistently ranked among China's top ten traditional Chinese patent medicine-exporting enterprises.

UXN Co., Ltd., a South Korean biomedical company listed on the KONEX (Korea New Exchange) for startups and SMEs, specializes in the development of enzyme-free continuous glucose monitoring (CGM) technology. Its proprietary mesoporous platinum electrode sensor offers high sensitivity, long lifespan, calibration-free operation, and low interference. The product series has completed human clinical trials and is currently undergoing regulatory approval by Korea's Ministry of Food and Drug Safety (MFDS). UXN plans to expand into China, the United States, and Europe, driving global commercialization and building an ecosystem for remote diabetes management and wearable medical devices.

宁夏山逗子杂粮绿色食品科技开发有限公司是一家集杂粮种植、加工、销售和熟食品加工为一体的民营生产企业，公司秉持“为耕者利、为食者福、为工者安、为国者责”的经营宗旨，坚持品质至上的经营理念，科学严谨的管理，永于创新、采用科学新技术为广大消费者生产出药食同源、纯天然、无污染、无公害的有机绿色杂粮养生保健品

Jiaxing Innocul Probiotics Co., Ltd(INNOCUL) is a manufacturer of premium probiotics for B2B customers, founded by scientists in Zhejiang province, China 2016, management team has near 20 years of expertise in probiotic R & D and production. INNOCUL offers proprietary functional probiotics, stable freeze-dried probiotic powder and tailor-made finished products, manufacturing facilities are certified GMP, ISO 22000 allergen-free, non-GMO, and HALAL. INNOCUL provides our partners with the full support from R & D to finished products, and fully meet your tailor-made needs in probiotic strains and finished products.